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Some compounds, characterized by phenylethenyl moiety, such as methyl cinnamate and caffeic acid
phenethyl ester, are able to inhibit C. albicans biofilm formation. On these bases, and as a consequence
of our previous work, we synthesized a series of cinnamoyl ester and amide derivatives in order to eval-
uate them for the activity against C. albicans biofilm and planktonically grown cells.
The most active compounds 7 and 8 showedP50% biofilm inhibition concentrations (BMIC50) of 2 lg/
mL and 4 lg/mL respectively, against C. albicans biofilm formation; otherwise, 7 showed an interesting
activity also against mature biofilm, with BMIC50 of 8 lg/mL.
 2016 Elsevier Ltd. All rights reserved.Candida albicans (C. albicans) is the most common fungal patho-
gen in clinical settings and it is responsible of infections that can
affect the skin and the mucosa or cause life-threatening systemic
disease.1,2 The mortality among patients with invasive candidiasis
is as higher than 40%, even when patients receive antifungal
therapy.3
One of the major problem related to the treatment of C. albicans
infections is therapeutic failure, especially due to the onset of ther-
apeutic resistance phenomena, which are very often associated
with the biofilm formation.4
Biofilms are defined as complex microbial communities encased
in a matrix of extracellular polymeric substances, that develops
when a community of microorganisms irreversibly adheres to an
inert or living surface. Contact with a solid surface triggers the
expression of a panel of enzymes, which catalyze the formation
of sticky polysaccharides that promote the surface colonization
and the microbial cells protection. This adherent community is
considered an important virulence factor because it is difficult to
eradicate and often responsible for treatment failures.5 Indeed,
the biofilm represents a physical barrier that prevents drugs from
entering and expressing their activity.In C. albicans the morphogenesis and the biofilm formation are
controlled by a complex mechanism of communication termed
quorum sensing (QS), a process that is sensitive to the cell density
in the biofilm population. The QS is based on the exchange and
sensing of low molecular weight signal compounds,6 in particular,
three substances have been identified as QS molecules: farnesol,
phenylethyl alcohol and tryptophol.7 However, the antifungal
resistance of C. albicans biofilm is complex and it involves not only
the physical barrier due to the polysaccharide layer, but a number
of different mechanisms, such as over-expression of efflux pumps,
genetic changes of drug targets, persister cells, biofilm-host
immune system interaction.8
Azoles currently used for the treatment of systemic infections
(e.g. fluconazole, itraconazole) have little effect against Candida
biofilms, even at high doses and in combination with caspofungin.9
For these reasons, new therapies are urgently needed to treat the
wide variety of Candida biofilm infections in the medical setting.
In literature there are few compounds able to inhibit C. albicans
biofilm formation,10 among them there are methyl cinnamate and
caffeic acid phenethyl ester (CAPE), characterized by phenylethe-
nyl moiety.11 Based on these evidences, in our previous work we
tested, against C. albicans planktonic and biofilm cells, a series of
caffeic and cinnamic acid derivatives (Chart 1).
By referring to the structure of CAPE and its biological proper-
ties,12–14 we synthesized several ester and amide compounds with
simple chains or several more complex groups. Furthermore, we
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Chart 1. Compounds characterized by a phenylethenyl moiety and our lead
compound 1.
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albicans biofilm. It was able to inhibit the biofilm formation and
to reduce the metabolic activity of preformed biofilm, better than
the reference drug fluconazole.
Our basic SAR study has showed that the conjugation of the car-
bonyl group with an unsaturated system seems to be relevant for
the anti-biofilm activity; furthermore, the presence of the hydrox-
ylic groups appears to be not necessary.15
In this paper we report the synthesis and the activity evalua-
tion, on C. albicans biofilm, of a new series of cinnamoyl ester
and amide derivatives that have been designed with the idea of
preserving the cinnamoyl moiety and removing the hydroxyl
groups of caffeic acid, in order to obtain an improved chemical sta-
bility and a simplified reaction work up.
We also investigated the importance of the nitro group, present
in our reference compound (1), forasmuch as, it is known from the
literature that compounds able to induce the production of reac-
tive oxygen species (ROS) possess a potential antibiofilm activ-
ity.16,17 The ROS are usually generated by in vivo electron
transfer processes that involve specific chemical functionalities
including aromatic nitro compounds.18 In this context, we have
synthesized several ester and amide derivatives combining the car-
boxylic function of cinnamic acid with different groups, including
nitro heterocyclic groups, azole and indole rings (Chart 2).
We also synthesized some molecular hybrids between cinnamic
acid and other compound endowed with own antifungal activity.
In particular, we have chosen molecular fragment of anti-biofilm
compounds as miconazole (7) and molecules that are active
against planktonic cells as fluconazole (8).19R
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Scheme 1. General procedure for the synthesis of 2–6, 9–10. (a) SOCl2, 2 h, reflux; (b) opportune alcohol or amine, TEA, DCM, 12 h, reflux (2–6, 9) or r.t. (10).
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between cinnamic acid and tryptamine, because it is demonstrated
that compounds, such as indole and 3-indolylacetonitrile, are able
to reduce biofilm formation and virulence, by the regulation of
NRG1, a transcriptional factor that influences filamentation and
biofilm formation in C. albicans.20
The synthetic procedures of the studied compounds are
illustrated in the Schemes 1 and 2; briefly, the cinnamic acid was
activated to cinnamoyl chloride by the treatment with SOCl2, then
the opportune alcohol or amine were added to synthesize the cor-
responding ester (2, 6) or amide (3–5, 9, 10).
The compounds 2, 5 and 10 were synthesized modifying the
procedures reported in literature.21–23
For the synthesis of the compound 2, the metronidazole was
obtained by extraction with dichloromethane after shattering
commercial tablets in warm water24; whereas, the 1-(3-nitropy-
ridin-2-yl)piperazine, necessary to synthesize compound 4, was
prepared as we have previously reported.25
Attempts to synthesize esters 7 and 8 using the above illus-
trated scheme were unsuccessful, then it was necessary to preven-
tively activate the alcoholic function by NaH before the reaction
with cinnamoyl chloride.
The detailed synthetic procedures, the analytical and spectro-
scopic data of new synthesized compounds are reported in the
supplementary material and are in agreement with the proposed
structures.
Cinnamic acid, its derivatives 2–10 and parent alcohol or amine
compounds, have been screened to evaluate the activity against
planktonically growing C. albicans cells and against C. albicans bio-
film formation and preformed. For the in vitro antifungal and anti-
biofilm experiments, described in detail in the supplementary
material, C. albicans ATCC 10231 was used. This strain is sensitive
to fluconazole on planktonic cells (MIC50 0.5 lg/mL) and it is resis-
tant in the different phases of biofilm formation (BMIC50 128 lg/
mL and >128 lg/mL respectively on biofilm formation and mature
biofilm). The minimal inhibitory concentration (MIC) was calcu-
lated and expressed as the lowest drug concentration at which a
significant decrease in turbidity (>50%) was detected in compar-
ison with the control in the absence of drug. The 50% inhibitory
concentration (BMIC50) were defined as the concentrations causing
50% inhibition of either biofilm formation or preformed biofilms
due to drug treatment.OH
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Scheme 2. General procedure for the synthesis of 7, 8. (a) NaH, CH3CN, 2 h, r. t. (7)
or 50 C (8); (b) cinnamoyl chloride, 12 h, r. t. (7) or 50 C (8).
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Table 1, where the MIC50 and BMIC50 values of the synthesized
cinnamic derivatives 2–10 are compared to the earlier published
compound 1, cinnamic acid and parent alcohol and amine
compounds.
In most cases the presence of the cinnamic moiety produces an
increase of the antibiofilm activity, particularly for the biofilm for-
mation, as can be observed for compounds 2, 6, 7, 8 and 10 with
respect of the corresponding amines or alcohols. The only excep-
tion is presented by the compound 5, for which was observed an
increase of the BMIC50 values compared to the corresponding
amine.
The activities of compounds 2–5 on mature biofilm, on
biofilm formation, as well on planktonic cells, range from 32 to
>128 lg/mL. These data indicate that the replacement of the
nitrofuran moiety of the reference compound 1 with other
nitroheterocyclic groups, as nitroimidazole (2), nitropyridine and
(4) nitrobenzothiazole (5), or nitrophenyl group (3), resulted in a
significant reduction of the antibiofilm activity. Furthermore, the
removal of the nitro group from the compound 1 to obtain the
furan derivative 6 did not produce significant changes against bio-
film in formation but it reduced the activity on preformed biofilm,
as the BMIC50 increased from 64 to 128 lg/mL, and more markedly
on planktonic cells, as the MIC50 increased from 2 to 64 lg/mL.
Taken together, the activity data for compound 2–5 compared
to 1 indicate that the presence of nitrofuran moiety appears to
be critical to obtain the anti-biofilm activity. These data also sug-
gest that the antibiofilm activity of the nitrofuran moiety could
be due to a combined action on planktonic cells and on the biofilm,
especially in the mature phases.
It is noteworthy that in this study we have identified other new
interesting anti biofilm compounds. Cinnamic acid not showed
antibiofilm activity, as reported in Table 1, but combining it with
molecular fragments that are present in antifungal drugs, new
compounds have been obtained with antibiofilm activities.
In particular, the most active derivative 7, containing a molecu-
lar fragment of miconazole, has shown inhibition of biofilm in for-
mation at the concentration of 2 lg/mL and reduction in metabolic
activity of preformed biofilm at 8 lg/mL, lower than the lead com-
pound 1 (16 and 64 lg/mL, respectively) and the reference drug
fluconazole (128 and >128 lg/mL, respectively).
Finally, the esterification of fluconazole with cinnamic acid, to
produce the hybrid compound (8), it has led to a significant
increase in the activity on biofilm formation (BMIC50 4 lg/mL vs
128 lg/mL) and in minor extent on preformed biofilm. On the
other hand, the hybrid of cinnamic acid with tryptamine (10) have
produced an enhancement of the anti-biofilm activity, selectively
against biofilm in formation, with the reduction of BMIC50 value
from 128 lg/mL to 8 lg/mL.
In conclusion, the synthesis of amide and ester derivatives of
cinnamic acid has allowed to identify new compounds endowed
of antibiofilm activity, particularly effective in the early phases of
biofilm formation. The cinnamic moiety does not seem to act as
a simple lipophilic carrier but instead appears to be responsible
for antibiofilm activities; in fact, in most cases, quite active esters
or amides were obtained from amines or alcohols which do not
have activity on biofilm (compounds 1, 2, 3 and 6 vs parent
alcohols or amides). Furthermore, the cinnamic group enhances016), http://dx.doi.org/10.1016/j.bmcl.2016.10.091
Table 1
Antifungal activity of compounds 1–10, cinnamic acid and the parent compounds against C. albicans ATCC 10231 biofilm and planktonic cells.
Ester or amide compound BMIC50 (lg/mL) MIC50 (lg/mL)
Planktonic cells
Parent alcohol or amine
Mature biofilm Biofilm formation
1 64 16 2
64 64 16
OOH NO2
2 >128 32 128
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N
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The inhibition of biofilm formation and destruction of pre-formed biofilm by different compounds were evaluated by measuring the metabolic activity of cells within the
biofilm (XTT assay). The BMIC end point for biofilm is based on the lowest drug concentration producing a decrease of 50% metabolic activity relative the untreated growth
control. MIC end point for planktonic cells is based on lowest drug concentration that prevented 50% of growth with respect to the untreated control. At least two experiments
were performed on two separate dates for each compound tested in triplicate. The results were expressed as median.
4 D. De Vita et al. / Bioorganic & Medicinal Chemistry Letters xxx (2016) xxx–xxxthe weak antibiofilm activity of the 1-(2,5-dichlorophenyl)-2-(1H-
imidazol-1-yl)ethanol, the parent alcohol of ester 7, and confers
good antibiofilm activity to fluconazole, the parent alcohol of ester
8.
The activity data obtained for these cinnamic derivatives also
indicate that the approach of combining into a hybrid, two molec-
ular fragments characterized by their own activities, could bePlease cite this article in press as: De Vita D., et al. Bioorg. Med. Chem. Lett. (2advantageously exploited to develop new compounds with anti-
biofilm activity.
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